FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasiiiigion,	D.C.	20349	

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
notruction 1(h)	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Stonehouse Jon P			<u> </u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC						(Ched	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Loot)	/[Tirot)	(Middle)	- ^I	BCRX	J						X	Officer (give title		(specify
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200				3. Date of Earliest Transaction (Month/Day/Year) 02/27/2017							President & CEO					
(Street) DURHAM NC 27703				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
	IVI IN		2//03										Form file Person	ed by More	than One Rep	orting
(City)	(S	State)	(Zip)													
		Ta	able I - Non-D	erivat	ive S	ecurities	Acc	quired,	Dis	posed of	f, or Ben	eficially	Owned			
Da		ate	h/Day/Year) Execution		2A. Deemed 3. Execution Date, if any (Month/Day/Year) 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			and 5) Securities Beneficially Owned Follo		i. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D) Price		Transaction	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
			Table II - De (e.			curities <i>F</i> Ils, warra							wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		Derivative Expira		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	n(s)	
Emp. Stock Option (Right to Buy)	\$5.51	02/27/2017		A		500,000(1)		02/27/20	18	02/27/2027	Common Stock	500,000	\$0	500,000) D	

Explanation of Responses:

1. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of attorney

03/01/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.